• OptimizeRx’s Q3 2026 net income rose 53% year-over-year to $1.2 million, while revenue fell 17% to $21.6 million.
• Debt principal repayments totaled $9.3 million since June 30, 2026, reducing outstanding principal to $10.4 million.
• Management reported growth in contracted revenue for 2027 and renewed fourth-quarter spending from a previously significant customer.
• FY26 revenue guidance was revised to $87 million-$93 million due to in-year contracted revenue tracking below prior-year levels.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OptimizeRx Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611111601PRIMZONEFULLFEED9875211) on November 11, 2026, and is solely responsible for the information contained therein.